Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 208 posts found.

Eli Lilly to acquire DICE Therapeutics for immunology innovations

June 21, 2023
Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology

Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023
Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …

News

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …

News
lilly_entrance_web

Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

June 28, 2021
Sales and Marketing Eli Lilly, semaglutide, type 2 diabetes

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C and body weight reductions compared …

News

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

June 25, 2021
Medical Communications Alzheimer's, Eli Lilly, FDA

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …

News

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

News

Eli Lilly and MiNA Therapeutics to collaborate on saRNA research

May 12, 2021
Research and Development Eli Lilly

Eli Lilly and MiNA Therapeutics have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small …

News
lilly_entrance_web

Eli Lilly to collaborate with diabetes tech companies on insulin pen

May 10, 2021
Sales and Marketing Eli Lilly, diabetes

Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the …

News
Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

April 19, 2021
Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

News
Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

News
Eli Lilly building

Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial

March 11, 2021
COVID-19, Eli Lilly, covid-19 treatment

Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …

News
lilly_entrance_web

Lilly’s cancer drug Retsevmo gets UK approval for multiple indications

March 10, 2021
Research and Development Cancer, Eli Lilly, MHRA

The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.

News
credit_-_daniel_leal-olivas-afp

CHMP recommends Lilly’s bamlanivimab for COVID-19 patients

March 8, 2021
Sales and Marketing COVID-19, EMA, Eli Lilly

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …

News
lilly_entrance_web

Eli Lilly’s diabetes drug tirzepatide reduces blood glucose and weight in Phase III trials

February 18, 2021
Eli Lilly, diabetes

Eli Lilly’s tirzepatide led to significant haemoglobin A1C (HbA1C) and body weight reductions from baseline in adults with type 2 …

News
Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

February 15, 2021
Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024